Interim report July-September 2022
Stockholm, November 3, 2022 - Vicore Pharma Holding AB (publ) publishes the interim report for the third quarter 2022.Important events during the third quarter · In August, Vicore announced late-breaker presentation of interim data with C21 in the IPF trial (AIR) at the 2022 ERS congress. · In September, Vicore announced continued stabilization and increase in lung capacity with C21 in the IPF trial (AIR) and a second interim analysis planned for Q4 2022. · In September, Vicore announced that the phase 3 trial with C21 in COVID-19 (ATTRACT-3) did not reach the primary and